AFP - L3% and DCP as tumor markers in patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolisation (TACE)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00000812

Enrollment

Registered

2011-05-03

Start date

2010-06-10

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C22.0

Interventions

Group 1: Patients with HCC who are treated with transarterial chemoembolisation are enrolled in this trial. Before TACE serum samples are taken in order to perform the measurement of AFP, AFP-L3% and

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: - age between 18 and 80 - diagnosis of HCC according the AASLD criteria - TACE is planned - resection is impossible

Exclusion criteria

Exclusion criteria: - liver tumor of unknown origin - other liver tumors - TACE is impossible

Design outcomes

Primary

Measure	Time frame
- evaluation of the course of the liver cancer markers AFP, AFP-L3% and DCP after transarterial chemoembolisation. - markers are measured before TACE, 1 month and 3 months after TACE. 3 months after TACE a MRI or CT imaging is performed to evaluate the therapeutic response - analysing the quality of life before and after TACE (3 months after TACE) using the EORTC- QLQ- C30.	—

Secondary

Measure	Time frame
- long-term survival ( 1-year, 3- year, 5-year- survival) - progression- free – time	—

Countries

Germany

Contacts

Public ContactMichael Schultheiss

UKL Freiburg, Med. Klinik II

michael.schultheiss@uniklinik-freiburg.de0761-270-33080

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026